New Cancer Drug Boosts Weight, Activity in Patients
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition
Drug breakthrough provides new hope for cancer patients with cachexia
Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
New cancer cachexia treatment boosts weight gain and patient activity
A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.
ESMO 2024: Pfizer’s cachexia drug provides meaningful weight gain
Ponsegromab reached a clinically meaningful 5.6% mean weight increase at the high dose level in patients with cancer cachexia.
ESMO: Pfizer drug helps cancer patients gain weight
Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically meaningful, and Pfizer is now thinking about starting a phase 3 programme for the drug next year.
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
Experimental drug helps cancer patients regain weight, study shows
Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, offering fresh promise for treating the dangerous muscle-wasting condition.
Pfizer therapy succeeds in mid-stage trial for cancer-related weight loss
Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial. Read more here.
Medpage Today on MSN1d
Novel Agent Effective for Cancer Wasting Disorder
Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...
Pfizer: Potential cachexia cancer drug shows life-saving promise
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
Understanding cancer patients with malnutrition and metabolic dysfunction
Cancer patients frequently experience metabolic dysfunction, leading to severe weight loss correlating with a poor prognosis.
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Maxim Group analyst Jason McCarthy maintained a Buy rating on Artelo Biosciences (ARTL – Research Report) yesterday and set a price ...
The Pharma Letter3d
ESMO 2024: Positive Phase II results for Pfizer’s ponsegromab in cancer cachexia
The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...